Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.

OBJECTIVE To determine the correlation of cell adhesion molecules (osteopontin-c, E-cadherin and β-catenin) with clinicopathological characteristics in breast cancer. METHODS Immunostaining of osteopontin-c, E-cadherin and β-catenin were conducted in 170 samples of breast cancer and 30 samples of adjacent normal breast tissues. The correlation of osteopontin-c, E-cadherin and β-catenin expression level with clinicopathological characteristics was evaluated by Pearson's chi-square and Wilcoxon rank-sum test. Univariate and multivariate Cox hazard regression model was used to assess the prognostic values of osteopontin-c, E-cadherin and β-catenin in clinical outcome of breast cancer. RESULTS A higher level of osteopontin-c whereas lower levels of E-cadherin and β-catenin were observed in breast cancer as compared with the normal breast tissues. The expression of osteopontin-c was negatively associated with the expression of E-cadherin and β-catenin. The expression of osteopontin-c correlated with lymph node metastasis, and advanced TNM stage and histologic grade. The expression of E-cadherin correlated with low histologic grade; and β-catenin with low TNM stage and histological grade. Moreover, high osteopontin-c level correlated with tumor recurrence or metastasis as well as triple negative subtype. The expression of osteopontin-c was an independent prognostic factor for both disease-free and overall survival of breast cancer patients. CONCLUSION The data suggest that the expression of osteopontin-c could serve as a prognostic factor of breast cancer.

[1]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Schwartz,et al.  Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. , 1994, Circulation research.

[3]  Boecker,et al.  Immunophenotypic and prognostic analysis of E‐cadherin and β‐catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44 , 1999, Histopathology.

[4]  Mansoor M Ahmed,et al.  The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. , 2006, Current molecular medicine.

[5]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[6]  V. Bramwell,et al.  Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[7]  F. Walsh,et al.  Epithelial (E‐) and placentae (P‐) cadherin cell adhesion molecule expression in breast carcinoma , 1993, The Journal of pathology.

[8]  Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. , 1999 .

[9]  S. Pinder,et al.  An immunohistochemical examination of the expression of E‐cadherin, α‐ and β/γ‐catenins, and α2‐ and β1‐integrins in invasive breast cancer , 1999, The Journal of pathology.

[10]  E. Thompson,et al.  Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[11]  Dino Amadori,et al.  The global breast cancer burden: variations in epidemiology and survival. , 2005, Clinical breast cancer.

[12]  S. Stock,et al.  Regulation of Breast Cancer-induced Bone Lesions by β-Catenin Protein Signaling* , 2011, The Journal of Biological Chemistry.

[13]  Christian Wittekind,et al.  Cancer Invasion and Metastasis , 2005, Oncology.

[14]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[15]  W. Jiang,et al.  Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. , 2008, Anticancer research.

[16]  Mi-Sook Lee,et al.  Significance of E-cadherin/β-catenin complex and cyclin D1 in breast cancer , 2002 .

[17]  Lan Chao,et al.  Increased expression of osteopontin in patients with triple‐negative breast cancer , 2008, European journal of clinical investigation.

[18]  M. Takeichi,et al.  Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.

[19]  G. Weber,et al.  Osteopontin‐c is a selective marker of breast cancer , 2008, International journal of cancer.

[20]  A. Chambers,et al.  Activation of MMP‐2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent , 1998, International journal of cancer.

[21]  A. Ribeiro-Silva,et al.  Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. , 2008, The International journal of biological markers.

[22]  P. Kuo,et al.  Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer , 2009, BMC Research Notes.

[23]  M. Rubin,et al.  E-cadherin expression in primary carcinomas of the breast and its distant metastases , 2003, Breast Cancer Research.

[24]  D. Miles,et al.  Retention of the expression of E‐cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast , 2001, The Journal of pathology.

[25]  F. O'Malley,et al.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  David L Rimm,et al.  Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. , 2006, Cancer research.

[27]  J. Jónasson,et al.  Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. , 1999, European journal of cancer.

[28]  F. Akiyama,et al.  Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer , 2014, Breast Cancer.

[29]  Barbara L. Smith,et al.  The effect of tumor size and lymph node status on breast carcinoma lethality , 2003, Cancer.

[30]  M. C. Ling,et al.  Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells , 1999, Oncogene.

[31]  E. Rollo,et al.  Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme , 1995, Clinical & Experimental Metastasis.

[32]  R. Samant,et al.  Osteopontin: an effector and an effect of tumor metastasis. , 2010, Current molecular medicine.

[33]  Xinjie Lin,et al.  Osteopontin Deficiency in Rat Vascular Smooth Muscle Cells is Associated with an Inability to Adhere to Collagen and Increased Apoptosis , 2000, Laboratory Investigation.

[34]  A. Leong,et al.  The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment , 2011, Pathobiology.

[35]  G. Weber,et al.  An osteopontin splice variant induces anchorage independence in human breast cancer cells , 2006, Oncogene.

[36]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[37]  Kevin Hughes,et al.  Predicting the survival of patients with breast carcinoma using tumor size , 2002, Cancer.

[38]  F. O'Malley,et al.  Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. , 1997, Archives of pathology & laboratory medicine.

[39]  G. Casey,et al.  Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435 , 2006, Clinical & Experimental Metastasis.

[40]  A. Chambers,et al.  Osteopontin‐induced, integrin‐dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met) , 2000, Journal of cellular biochemistry.

[41]  L. Cai,et al.  Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. , 2011, Cancer biotherapy & radiopharmaceuticals.

[42]  A. Chambers,et al.  Overcoming obstacles to metastasis ‐ defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells , 1994, Journal of cellular biochemistry.

[43]  T. Rowlands,et al.  Cadherins and catenins in breast cancer. , 2005, Current opinion in cell biology.

[44]  G. Casey,et al.  Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1 , 2008, International journal of cancer.

[45]  S. Kuo,et al.  Triple negative breast carcinoma is a prognostic factor in Taiwanese women , 2009, BMC Cancer.

[46]  C. Gilles,et al.  The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. , 1998, Experimental cell research.

[47]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[48]  N. Duraker,et al.  Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes , 2005, Cancer.

[49]  G. Weber,et al.  Osteopontin is a marker for cancer aggressiveness and patient survival , 2010, British Journal of Cancer.

[50]  D. Fennell,et al.  Wnt–β-catenin–Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer , 2011, British Journal of Cancer.

[51]  G. Weber,et al.  Categorical meta-analysis of Osteopontin as a clinical cancer marker. , 2011, Oncology reports.